Lv1
40 积分 2025-11-26 加入
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial
21小时前
已完结
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial
29天前
已完结
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications
30天前
已完结
Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine
1个月前
已完结
Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia
1个月前
已完结
Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission
1个月前
已完结
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications
5个月前
已完结
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications
5个月前
已完结
Post-HCT maintenance therapy for AML: who, when, why, how long?
6个月前
已完结
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
6个月前
已完结
皖公网安备34019202002308
